Achieve Life Sciences (SP4P) Price & Analysis

3 Followers

SP4P Stock Chart & Stats

€5.35

-€0.10(-1.83%)

At close: Jul 24 4:00 PM EDT

€5.35

-€0.10(-1.83%)

Day’s Range― - ―

52-Week Range€2.17 - €6.65

Previous CloseN/A

Volume0.00

Average Volume (3M)29.00

Market Cap

€750.84M

Enterprise Value€438.27

Total Cash (Recent Filing)€187.30M

Total Debt (Recent Filing)€14.95M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Nov 05, 2026

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.55

Shares Outstanding102,902,490

10 Day Avg. Volume2

30 Day Avg. Volume29

Financial Highlights & Ratios

PEG Ratio-4.93

Price to Book (P/B)10.07

Price to Sales (P/S)0.00

P/FCF Ratio-4.38

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.13

Price Target Upside126.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.18

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Funding PositionThe substantial financing improves runway for regulatory work, commercialization and the vaping trial. It gives Achieve flexibility to advance its lead asset without relying solely on immediate capital markets access.

Robust Phase III EfficacyStrong, statistically supported efficacy across more than 1,600 Phase III participants could differentiate cytisinicline in smoking cessation. Benefits in patients with prior treatment exposure may support adoption and a broader commercial opportunity.

Long-Dated Product IPLong-duration intellectual property could protect cytisinicline from direct generic competition for many years after approval. This would support a durable commercial franchise and give Achieve time to expand into vaping cessation.

Bears Say

Pre-Commercial Financial ProfileAchieve remains entirely dependent on successful clinical development and future approval because it has no commercial revenue. Widening losses indicate a high expense base and limited earnings visibility until cytisinicline can generate sales.

Cash Burn And Negative EquityPersistent cash burn means operations cannot currently fund themselves, while negative equity reduces balance-sheet flexibility. Continued development and commercialization therefore require external funding, increasing financing dependence and dilution risk.

Regulatory And Manufacturing DelayThe manufacturing-related FDA issue delays approval and the planned launch, while technology transfer to Adare introduces execution risk. Further regulatory or production problems could extend the timeline and increase development costs before commercialization.

Achieve Life Sciences News

Achieve Life Sciences price target lowered to $18 from $20 at Raymond James

Raymond James analyst Ryan Deschner lowered the firm’s price target on Achieve Life Sciences (ACHV) to $18 from...

5d ago

ACHV

Achieve Life Sciences initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor initiated coverage of Achieve Life Sciences (ACHV) with an Overweight rating and $13...

5d ago

ACHV

Achieve Life Sciences reports Q2 EPS (80c), consensus (16c)

“This quarter was about building Achieve to match the significant opportunity of cytisinicline,” said Andrew Goldberg, CEO of...

10d ago

ACHV

Achieve Life Sciences initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Achieve Life Sciences (ACHV) with an Outperform rating and $17 price target Published...

17d ago

ACHV

Five Below, Achieve, Tronox, Brightstar, Inovio Trending

Analysts are intrested in these 5 stocks: ( ($FIVE) ), ( ($ACHV) ), ( ($TROX) ), ( ($BRSL)...

7d ago

INO

ACHV

Achieve Life Sciences Launches $150M ATM Equity Program

Achieve Life Sciences ( ($ACHV) ) just unveiled an announcement. On August 14, 2026, Achieve Life Sciences entered...

7d ago

ACHV

Achieve Maintained at Buy as Cytisinicline Resubmission and Strong Cash Runway Support Unchanged $13 Price Target

Analyst Gary Nachman from Canaccord Genuity maintained a Buy rating on Achieve Life Sciences and keeping the price...

10d ago

ACHV

Analyst Maintains Buy Rating on Achieve Life Sciences with Unchanged $17 Price Target, Backed by Cytisinicline Launch Readiness and FDA Pathway Clarity

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Achieve Life Sciences,...

10d ago

ACHV

Achieve Maintains Strong Cash Position and Clear FDA Path; Brandon Folkes Reiterates Buy Rating and Unchanged $12 Price Target

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences, retaining the price target...

10d ago

ACHV

ACHV, HUM, APTV, FIS, ADM Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($ACHV) ), ( ($HUM) ), ( ($APTV) ), ( ($FIS)...

14d ago

ADM

FIS

ACHV Upcoming Earnings Report: What to Expect?

Achieve Life Sciences (ACHV) is scheduled to report 2nd quarter earnings on 08/06/2026. Regarding Q2 estimates, Wall Street...

18d ago

ACHV

Achieve Life Sciences Expands Authorized Shares After Stockholder Vote

An update from Achieve Life Sciences ( ($ACHV) ) is now available. At its Annual Meeting of Stockholders...

2M ago

ACHV

Achieve Life Sciences added to Russell 2000 Index

Achieve Life Sciences (ACHV) announced that it has been added to the Russell 2000 Index, effective June 26...

2M ago

ACHV

Achieve Life Sciences resumed with a Strong Buy at Raymond James

Raymond James resumed coverage of Achieve Life Sciences (ACHV) with a Strong Buy rating and $20 price target...

2M ago

ACHV

SP4P FAQ

What was Achieve Life Sciences Inc’s price range in the past 12 months?

Achieve Life Sciences Inc lowest stock price was €2.17 and its highest was €6.65 in the past 12 months.

What is Achieve Life Sciences Inc’s market cap?

Achieve Life Sciences Inc’s market cap is €750.84M.

When is Achieve Life Sciences Inc’s upcoming earnings report date?

Achieve Life Sciences Inc’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.

How were Achieve Life Sciences Inc’s earnings last quarter?

Achieve Life Sciences Inc released its earnings results on Aug 10, 2026. The company reported -€0.685 earnings per share for the quarter, missing the consensus estimate of -€0.141 by -€0.544.

Is Achieve Life Sciences Inc overvalued?

According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Achieve Life Sciences Inc pay dividends?

Achieve Life Sciences Inc does not currently pay dividends.

What is Achieve Life Sciences Inc’s EPS estimate?

Achieve Life Sciences Inc’s EPS estimate is -0.17.

How many shares outstanding does Achieve Life Sciences Inc have?

Achieve Life Sciences Inc has 102,902,490 shares outstanding.

What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?

Achieve Life Sciences Inc reported an EPS of -€0.685 in its last earnings report, missing expectations of -€0.141. Following the earnings report the stock price went up 0.893%.

Which hedge fund is a major shareholder of Achieve Life Sciences Inc?

Currently, no hedge funds are holding shares in DE:SP4P

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Achieve Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

223.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Achieve Life Sciences Inc

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Achieve Life Sciences (SP4P) Earnings & Revenues

Historic Earnings Reports

SP4P Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.View all DE:SP4P earnings summaries

SP4P Stock 12 Month Forecast

Average Price Target

€12.13

▲(126.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","18":"€18","5.25":"€5.25","9.5":"€9.5","13.75":"€13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.1258096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.1307818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5629048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.25,9.5,13.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.4,6.301985353846154,7.203970707692308,8.105956061538462,9.007941415384616,9.909926769230768,10.811912123076922,11.713897476923076,12.61588283076923,13.517868184615384,14.419853538461538,15.321838892307692,16.223824246153846,{"y":17.1258096,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.4,5.917752446153846,6.4355048923076925,6.953257338461539,7.471009784615385,7.988762230769231,8.506514676923077,9.024267123076923,9.542019569230769,10.059772015384615,10.577524461538461,11.095276907692307,11.613029353846153,{"y":12.1307818,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.4,5.6433003692307695,5.886600738461539,6.129901107692308,6.373201476923077,6.616501846153846,6.859802215384615,7.103102584615385,7.3464029538461535,7.5897033230769235,7.833003692307692,8.076304061538462,8.319604430769232,{"y":8.5629048,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.595,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.655,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.515,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.165,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.785,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >